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Abstract 
Galactokinase, the enzyme which catalyses the first committed step in the Leloir pathway, has 
attracted interest due to its potential as a biocatalyst and as a possible drug target in the treatment 
of type I galactosemia.  The mechanism of the enzyme is not fully elucidated.  Molecular dynamics 
(MD) simulations of galactokinase with the active site residues Arg-37 and Asp-186 altered predicted 
that two regions (residues 174-179 and 231-240) had different dynamics as a consequence.  
Interestingly, the same two regions were also affected by alterations in Arg-105, Glu-174 and Arg-
228.  These three residues were identified as important in catalysis in previous computational studies 
on human galactokinase.  Alteration of Arg-105 to methionine resulted in a modest reduction in 
activity with little change in stability.  When Arg-228 was changed to methionine, the enzyme’s 
interaction with both ATP and galactose was affected.  This variant was significantly less stable than 
the wild-type protein.  Changing Glu-174 to glutamine (but not to aspartate) resulted in no 
detectable activity and a less stable enzyme.  Overall, these combined in silico and in vitro studies 
demonstrate the importance of a negative charge at position 174 and highlight the critical role of the 
dynamics in to key regions of the protein.  We postulate that these regions may be critical for 
mediating the enzyme’s structure and function. 
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Introduction 
Galactokinase (EC 2.7.1.6) catalyses the ATP-dependent site and stereospecific phosphorylation of 
the hexose monosaccharide galactose [1, 2].  This reaction is critical since it forms the first 
committed step of the Leloir pathway of galactose metabolism [3].  This pathway is required for the 
conversion of galactose into the glycolytic intermediate glucose 6-phosphate since hexokinase (EC 
2.7.1.1; the first enzyme of the glycolytic pathway) has negligible activity with galactose [4].  The 
Leloir pathway has particular significance in young mammals since the main sugar present in milk is 
lactose, a disaccharide of glucose and galactose.  Reduced activity of any of the enzymes in the Leloir 
pathway can result in the inherited metabolic disease galactosemia [5].  This disease has a wide 
spectrum of manifestations ranging from alterations in blood chemistry with only mild effects for the 
patients to death in childhood [6].  Mutations in the gene encoding galactokinase (GALK1) can result 
in type II galactosemia in humans and other mammals [7, 8].  This is considered to be the mildest 
form of galactosemia with early onset cataracts being the most important manifestation.  These 
cataracts can be managed by diet or surgery and there appear to be few long-term complications for 
the patients [9].  In more severe forms of the disease (types I and III galactosemia) more significant 
pathology is thought to be linked to the build up of excess galactose 1-phosphate, the product of the 
reaction catalysed by galactokinase [10, 11].  Therefore, considerable efforts have been made to 
identify specific inhibitors of galactokinase in order to block the reaction it catalyses [12-17].  In 
effect, galactokinase inhibition would convert the more severe forms of galactosemia into the more 
manageable type II [9]. 
Galactokinase has also attracted some interest as a potential biocatalyst [18].  The site-specific 
modification of monosaccharides is chemically challenging.  However, galactokinase targets C1-OH for 
phosphorylation [19].  The high specificity of the human and yeast enzymes towards α-D-galactose 
(and some closely related sugars) limits their application in the synthesis of a wider range of sugar 1-
phosphates [19-21].  Consequently, a number of studies have focussed on identifying galactokinases 
with broader specificity or broadening the specificity of the enzyme [22-29].  Many bacterial 
galactokinases have broader specificity than the human or yeast enzymes [30].  For example, the 
Escherichia coli enzyme catalyses the phosphorylation of a range of galactose derivatives, but is 
inactive with D-glucose [26].  Its activity with fluorinated galactose derivatives enabled its use in the 
enzymatic synthesis of the O-fluoroglucoside of N-methylanthranilate and fluorinated Thomsen–
Friedenreich (T) antigens [31, 32].  The promiscuity of the E. coli enzyme has been expanded by 
protein engineering methods to include a wider range of D- and L-sugars [22, 23, 25].  Galactokinase 
from Bifidobacterium infantis is active with D-galacturonic acid and can also use a variety of 
phosphate donors instead of ATP including dATP, GTP, dGTP, ITP and dTTP [33].  This versatility has 
enabled the use of the enzyme in the synthesis of Galacto-N-biose derivatives [34].  Streptococcus 
pneumoniae TIGR4 galactokinase is active with D-glucose, some L-monosaccharides and, unusually, 
with N- acetyl-D-galactosamine [35, 36].  This enzyme has been applied in the synthesis of complex 
oligosaccharides (e.g. globotriose) and UDP-sugars [37-39]. 
The catalytic mechanism of galactokinase is generally accepted to involve the initial removal of a 
proton from the C1-OH and it is believed that this is done by an aspartate residue acting as a base in 
the active site [2, 40].  This generates a highly nucleophilic, negatively charged species which attacks 
the oxygen atom bridging the β- and γ-phosphates of ATP.  The γ-phosphate is thus transferred to the 
galactose molecule and ADP is released.  The initial state of the enzyme is regenerated by loss of the 
proton to water.  This mechanism is not universally accepted [41].  Galactokinase is a member of the 
GHMP kinase family of enzymes (named from some of the enzymes originally assigned to the family:  
galactokinase, homoserine kinase, mevalonate kinase and phosphomevalonate kinase) [42, 43].  
While the majority of these enzymes have an aspartate (or glutamate) residue in a structurally 
equivalent position to the putative active site base in galactokinase, at least one member does not.  
In homoserine kinase (EC 2.7.1.39) the equivalent residue is an asparagine, a residue which lacks the 
capacity to act as a base in this manner [44, 45].  It has been proposed, based on crystal structures 
and enzyme kinetic analysis, that homoserine kinase catalyzes the reaction partly by stabilizing the 
transition state [44].  It is possible that, in this enzyme, negatively charged oxygens on the γ-
phosphate of ATP abstract the proton from homoserine facilitating a direct transfer of the phosphate 
group [2].  Furthermore, in order to act as a base capable of removing a proton from the 
monosaccharide, the aspartate in galactokinase would need a pKa value considerably higher than 
that of the free amino acid (4.8 [46]) or the pKa of the C1-OH would need to be substantially reduced.  
Such alterations are possible in the interior of proteins.  However, previous computational chemistry 
work suggests that the pKa of this active site aspartate (Asp-186) in human galactokinase is 5.3-6.3 
[47].  While this is displaced from the free solution value, it may not be sufficient to facilitate transfer 
of the proton.  Nevertheless, a number of studies have demonstrated that this aspartate is critical for 
the function of galactokinase from a variety of species [16, 40, 47, 48].  In addition, an adjacent 
arginine residue (Arg-37 in human galactokinase) is also believed to be important and may play a role 
in modifying the pKa of the aspartate or stabilising the negative charge that develops on the sugar as 
it loses the proton [40].  Experiments in which active site residues are altered using site-directed 
mutagenesis are always compounded by the possibility that they may also cause alterations to the 
protein’s structure or stability.  In the case of Asp-186 in human galactokinase, alteration to either 
asparagine or alanine decreased the protein’s resistance to denaturation by urea [47].  Therefore, it 
is difficult to deduce that the loss of enzyme activity resulting from these alterations is caused 
entirely by the loss of chemical functionality at the active site. 
In an attempt to resolve some of these mechanistic issues, we previously conducted a detailed 
quantum mechanics/molecular mechanics (QM-MM) study of galactokinase [49].  This predicted that 
Asp-186 does not, directly, participate in the reaction and that there is direct transfer of the 
phosphate group from ATP to galactose.  Its role may be to polarise and weaken the oxygen-
hydrogen bond in C1-OH facilitating the direct attack by ATP [47, 49].  This study also identified a 
number of other residues which may play a key role in the enzyme’s mechanism.  Arg-105 and Glu-
174 were predicted to cooperate in the formation of a hydrogen bonding network which restricts the 
mobility of ATP in the active site.  Arg-228 may stabilise the transient negative charge which develops 
on the oxygen bridging the β- and γ-phosphates of ATP during bind breakage [49]. 
A greater understanding of this enzyme’s mechanism is important for the development of selective 
inhibitors of galactokinase and the fully exploiting its potential as a biocatalyst.  Catalytically 
important residues could be sterically hindered or modified by drug-like molecules.  The dynamic 
behaviour of enzymes is critical to their functions, including specificity and catalysis [50, 51].  
Knowing the structural and dynamic requirements for catalysis may enable further engineering of 
the enzyme’s specificity.  Therefore, we conducted a combined molecular dynamics (MD) and 
enzymological study to further elucidate the roles of Arg-105, Glu-174 and Arg-228.   
 
Materials and Methods 
Molecular dynamics simulations 
Protein Preparation and Molecular dynamics simulations were carried out as described by Huang et 
al, 2013 [49]. Chain A of the GALK crystal structure (1WUU) was altered using Biovia Discovery studio 
(Dassault Systèmes), Ser230 and Leu231 were added, selenomethionine residues were varied back to 
native methionine, AMP.PNP was altered to ATP and Mg2+ and the two coordinating water molecules 
were added to the active site. Variants were produced using the mutate feature in Biovia Discovery 
studio. Partial and RESP charges of galactose, Mg2+ and ATP were determined as previously described 
using the Gaussian 09 package [52] and antechamber encoded in Amber 10 [53] respectively.  All MD 
simulations were carried out using the Amber 10 package  and the Amber Parm 99 forcefields [54].  
Prior to simulation the protein, ATP and galactose were soaked in a TIP3P water box using tleap 
encoded in Amber 10.  The dimensions of the box for all proteins were 71.071 Å X 80.431 Å X 87.517 
Å and the minimum distance to the boundary of the protein was set to 8 Å.  Sodium ions were added 
to neutralise the system WT. E174D, R37K and R228K required seven ions, E174Q, D186A and D186N 
required 6 ions, both R105M and R228M required eight ions and R37E required nine.  Minimisation 
and simulation steps were carried out as described by Huang et al [49].  The system was subjected to 
1250 steps of first steepest descent minimisation then conjugate gradient minimisation, the latter 
was carried out with a 0.5 kcal mol-1 Å-2 [55].  The system was then heated from 0K to 300K for 50ps 
and with a collision frequency of 5.0 ps-1, using the Langevin dynamics method [56].  Equilibration 
was then carried out using an NVT ensemble, a periodic boundary was applied and the system 
maintained at 300K for 50 ps.  Production simulation was then carried out for 7 ns with a time step of 
1 fs, reference pressure of 1 atm and at 300 K.  A cut-off distance for Van der Waals interactions was 
set at 10 Å and these long range interactions were calculated using the particle mesh Ewald method 
[57].  Hydrogen convalent bonds were constrained via the SHAKE method [58]. 
 
Analysis of simulations  
Simulations were monitored using perl encoded in Amber and resulting graphs produced using 
GraphPad Prism version 5.03 for Windows (GraphPad Software, San Diego California USA) 
(Supplementary Figure S1).  Cluster analysis, secondary structure analysis and RMSF calculations 
were performed using the ptraj command in Amber 10 and structures visualised using Biovia 
Discovery Studio.  VMD software [59] was used to visualise trajectories, the timeline plugin was used 
to visualise secondary structure and Normal mode wizard was used to carry out principal component 
analysis (PCA) both were calculated using 1 ns of equilibrated trajectory, determined by monitoring 
RMSD over time (Supplementary Figure S2) [60]. 
 
Expression and purification of human galactokinase 
Recombinant human galactokinase was expressed in, and purified from, Escherichia coli 
HMS174(DE3) as previously described except that cobalt agarose resin (His-Select, Sigma, Poole, UK) 
was used in place of nickel agarose [47, 61].  Site-directed mutations were carried out by the 
QuikChange method [62] and the mutated DNA sequences were verified (GATC Biotech, London, UK).  
Variant proteins were expressed and purified using the same protocol as used for the wild-type 
protein.  Purified proteins were stored in buffer A (50 mM Hepes-OH, pH 7.5, 150 mM NaCl, 10% 
(v/v) glycerol, 1 mM DTT), frozen at -80 °C in aliquots of 20-100 µl until required. 
 Steady-state kinetic analysis of galactokinase 
Galactokinase activity was measured by coupling the reaction to those catalysed by pyruvate kinase 
(EC 2.7.1.4) and lactate dehydrogenase (EC 1.1.1.27) [63].  Rates were measured (in triplicate) at 37 
°C in 96 well plates by monitoring the decline in absorbance at 340 nm in a Thermo Scientific 
Multiskan spectrum platereader.  The total reaction volume was 160 µl and each reaction contained 
50 mM Hepes-OH, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.4 mM phosphoenolpyruvate, 1mM NADH, 
10 %(v/v) glycerol.  Reactions were initiated by the addition of enzyme (125-690 nM depending on 
the variant), monitored for 30 min and the linear portion of the reaction extracted by visual 
examination.  Rates were converted to molar units using the extinction coefficient for NADH (6220 l 
mol-1 cm-1 [64]) and a standard curve to correct for the reduced pathlength in the 96 well plate. 
Typically reactions were arrayed in a eight by ten grid in which ATP concentration was varied along 
one axis and galactose along the other [20, 61].  This enabled the extraction of ten datasets with 
varying ATP concentration and constant galactose concentrations along with eight datasets with 
varying galactose concentration and constant ATP concentrations.  For each of these 18 datasets, 
rates were plotted against the variable substrate concentration and these data fitted to the 
Michaelis-Menten equation (1) using non-linear curve fitting as implemented in GraphPad Prism 6.0 
(GraphPad Software, CA, USA) [65, 66]: 
  
          
         
  (1) 
where v is the initial rate, Vmax,app is the apparent maximal rate, Km,app is the apparent Michaelis 
constant and [S] is the concentration of the variable substrate.  Note that these are apparent kinetic 
parameters since the experiment was carried out in sub-saturating concentrations of substrates.  
Since human galactokinase has an ordered ternary complex mechanism [61], the steady state 
constants were estimated by plotting the Vmax,app values obtained for the various constant 
concentrations of ATP against these ATP concentrations and fitting these data to equation (2) [67, 
68]: 
         
         
           
 (2) 
where Km,ATP is the Michaelis constant for ATP.  A similar process was used to determine Km,gal, the 
Michaelis constant for galactose. 
 Analytical methods 
Differential scanning fluorimetry (DSF) was used to estimate the thermal unfolding temperature (or 
“melting” temperature, Tm) essentially as previously described [69].  Galactokinase (6.8 µM) was 
mixed with Sypro Orange (Sigma; 5 ×; manufacturer’s concentration definition) in a total volume of 
20 µl.  Fluorescence was monitored as a function of temperature (25 °C to 90 °C 1°C per step, 5 
seconds each step) using a RotorGeneQ qPCR machine (Qiagen).  Data were analysed using 
RotorGeneQ software. 
Native gel electrophoresis was used to show the resistance of the protein to denaturation by the 
chaotropic compound urea.  A discrete band represents folded protein which becomes less discrete 
and more smeared as the urea concentration increases.  The protocol was based on that of Megarity 
et al [47]. Protein (2.55 μM) was incubated with increasing concentrations of Urea (0-2 M) in 10 mM 
HEPES-OH, pH 7.0 and in the presence of native loading buffer (125 mM Tris-HCl, pH8.8, 20%(v/v) 
glycerol, 1%(w/v) DTT and 0.0002%(w/v) bromophenol blue) for 30 min at 37 °C.  Samples were then 
immediately loaded onto 15% native polyacrylamide gels (378 mM Tris-HCl, pH 8.8) and 
electrophoresed for 3 h at 20 mA.  Gels were then stained using 0.25% (w/v) Coomassie Blue R250, 
10% (v/v) acetic acid and 45% (v/v) ethanol and destained in 5% (v/v) ethanol, 7.5% (v/v) acetic acid. 
Protein concentrations were estimated using Bradford’s method with BSA as a standard [70]. 
 
Results and Discussion 
Previously characterised active site variants have altered MD in key regions 
Previous studies have shown that Arg-37 and Asp-186 (and the equivalent residues in galactokinase 
from other species) are critical to human galactokinase’s function.  However, this could be due to loss 
of key functionality in the active site or destabilisation of the protein.  To gain further insight into 
this, we conducted molecular dynamics studies on R37K, R37E, D186N and D186A (variants 
previously characterised biochemically and shown to have reduced activity [47]). 
All of the active site variants studied showed a propensity for change in two regions adjacent to the 
active site (residues 174-179 and 231-240).  This indicates that these regions are susceptible to 
change when wild type (WT) human galactokinase is altered at the active site. In WT the 231-240 
region occurs primarily as alpha helix (65%) but in R37E, R37K and D186A the region exists for the 
highest percentage of time as a 310 helix (88%, 68% and 50% respectively) and D186N primarily as a 
turn (90.7%) (Figure 2a).  All variants show an increase in the presence of a turn in region 174-179 
(Figure 2b).  The proximity of these two regions to the catalytically important residues Glu-174 and 
Arg-228 is particularly interesting. The distance between Glu-174 and Mg2+ increases from 4.3 Å in 
most prevalent WT structure to approximately 6.4 Å in the presence of the turn (in the region 174-
179). The distance between Arg-228 and the Mg2+ increases from 4.8 Å to 5.4 Å when the adjacent 
region is a turn or decreases to 4.5 Å if the same region is a 310 helix (Figure 2c,d). 
These predicted structural and dynamic changes in galactokinase strongly suggest that alteration of 
either R37 or D186 results in more than changes to active site chemistry.  This is consistent with 
previous data that showed that alteration of these residues resulted in proteins that were less stable 
to denaturation by urea [47].  The MD simulation also suggests that the two regions identified here 
may be important in catalysis and for maintaining wild-type structure and dynamics. 
 
Arginine 105 is implicated in ATP binding 
Alteration of Arg-105 to methionine reduced the turnover number (kcat) approximately twofold (Table 
1; Supplementary Figure S3) and increased Km,ATP by approximately the same factor.  Consequently, 
the specificity constant (kcat/Km,ATP) was also reduced.  However, Km,gal was relatively unaffected.  This 
suggests that this residue has a role in the initial interaction between the enzyme and ATP, consistent 
with the predictions from previous computational studies [49].  The removal of the positive charge at 
this position has no major changes on the overall, predicted dynamics of the protein (Figure 3).  DSF 
indicated no significant alteration of Tm (55.4±0.2 °C) compared to WT (55.7±0.3 °C) indicating that 
stability towards thermal denaturation was not altered by this variation (Table 2; Supplementary 
Figure S4).  R105M also showed similar resistance to denaturation by urea to the wild-type 
(Supplementary Figure S5). 
Arg-105 was previously shown to form an electrostatic interaction with Glu-174 in a molecular 
dynamics simulation [49].  The simulation of the neutral alteration from arginine to methionine at 
this position predicted that this variant would cause drifting of all ligands and eventual covalent 
bonding of Glu-174 to Mg2+ [49].  MD carried out in this study indicated that region 231-240 has 
similar structural propensities to WT whereas the presence of a turn between 174-179 increased by 
60% (Figure 3a,b).  This was reflected by increased root mean square fluctuation (RMSF) and 
increased RMSD of normal modes in these two regions (Figure 3c,d), however increased or 
decreased flexibility in these two regions does not affect stability of the protein.  The MD simulation 
carried out for this study provided no evidence for an electrostatic interaction between Arg-105 and 
Glu-174 suggesting the effects on ATP binding are not due to interaction with Glu-174 (Figure 3e). 
 
Alteration of arginine 228 impacts on substrate interactions 
When Arg-228 was altered to either lysine or methionine there was a modest increase in turnover 
number and an increase in Km,ATP (Table 1; Supplementary Figure S3).  In the case of R228M, there 
was a substantial increase in Km,gal, however, the Michaelis constant for this substrate remains 
essentially unchanged in R228K. Both variants are significantly destabilised compared to the wild-
type (Table 2; Supplementary Figure S4, S5).  Similar to the Arg-105 mutants, the presence of the 
turn from 174-179 showed an increase to around 80% in both Arg228 variants (Figure 4a).  The 
region 231-240 is of particular note in R228K where the percentage of time as a turn increases to 
93% for residues 233 and 234.  However, there is a large increase in the percentage of time, during 
which the residues 235 and 236 form no secondary structure. This may partly explain to the 
significant decrease in Tm (Figure 4b; Table 2).  Another factor which may contribute to the decrease 
in Tm (particularly for R228M) is the increase in flexibility of multiple regions i.e. around residues 100 
and 350 (Figure 4c). 
 
A negative charge at position 174 is critical for catalysis 
Alteration of Glu-174 to aspartate resulted in an enzyme with steady state kinetic parameters very 
similar to the wild-type (Table 1, Supplementary Figure S3).  However, when the residue was altered 
to asparagine there was no detectable activity.  This suggests that the presence of the negative 
charge at this position is critical to the function of the enzyme.  However, the exact distance of this 
charge from the backbone is less critical (aspartate has a shorter side chain, compared to glutamate).  
E174D was not significantly destabilised compared to the wild-type; however, E174Q became 
unstable (Table 2; Supplementary Figure S4, S5). 
Despite being very similar to the wild-type, MD simulations of E174D indicated that this alteration 
introduces α-helix into the region 174-179 (Figure 5a).  The significant thermal destabilisation of 
E174Q is not explained by RMSF, which is generally similar to WT enzyme (figure 5c) but may be 
explained by the loss of structure in the 231-240 region:  approximately 99.6% of the time this region 
formed no defined secondary structure compared to 0% in the WT simulation (Figure 5b). Despite 
alteration in the propensity of secondary structures in the 231-240 and the 174-179 regions and 
alteration to RMSF per residue, E174D is not significantly different to WT in terms of kinetics or Tm 
which suggests that as long as the 231-240 region remains mostly structured the enzyme is stable. 
 
Conclusions 
These data demonstrate the critical role of Glu-174 in catalysis by galactokinase, supporting the 
predictions made in our previous computational chemistry study.  Our findings are consistent with 
both the active site base and direct attack mechanisms of catalysis.  However, they do highlight the 
fact that active site residues hypothesised to be involved in the active site base mechanism are also 
required for wild-type protein stability.  Therefore, loss of activity on alteration of these residues is 
insufficient evidence that they are vital for catalysis. 
Our findings further highlight the importance of the conformational dynamics of two regions in 
controlling the activity of this enzyme.  This knowledge may be important in the design of novel 
galactokinase inhibitors and engineered forms of the enzyme with novel specificities.  Compounds 
which induce structural and dynamic transitions similar to those seen in the more unstable forms of 
the protein are more likely to be successful inhibitors of the enzyme.  Manipulation of the dynamics 
of these regions may result in altered activity or specificity.  One previous observation is that 
increased promiscuity of human galactokinase is generally accompanied by reduced activity [27].  
Ensuring that the structural and dynamic behaviour of these regions remains close to wild-type 
(perhaps by introducing compensatory changes) may enable the identification of variant enzymes 
with broad specificity and high activity. 
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Figures 
Figure 1:  Residues considered in this study are part of, or close to, the active site:  Arg-37, Red; Arg- 
105 blue; Glu-174; yellow; Asp-186 purple and Arg-228 green. 
 
Figure 2:  Molecular dynamics simulations of five galactokinase variants previously shown to have 
reduced activity.  (a) Secondary structure of residues 231-240 showing percentage time during the 1 
ns of the stable trajectory (as determined from RMSD values) each secondary structure feature 
occurs. (b) Secondary structure of residues 174-179 (which are adjacent to active site) showing 
percentage time during the 1 ns of the stable trajectory (as determined from RMSD values) each 
secondary structure feature occurs. (c) Structures representing changes observed in residues 174-
179 (red) and 231-240 (yellow) and the distance from Glu-174 and Arg-228 to the Mg2+ ion. (i) The 
unstructured region at 174-179 and alpha helix at 231-240. (ii) Turn at 174-179 and 231-240. (iii) Turn 
at 174-179 and 310 helix at 231-240. 
 
Figure 3:  Molecular dynamics simulation of galactokinase R105M. (a) and (b) The secondary 
structures of residues 174-179 and 231-240 respectively. (c) RMSF of R105M by residue compared to 
the WT enzyme.  (d) RMSD by residue (calculated using NMWiz plugin of VMD) Normal modes 
calculated by the principle component method and subtracted from values obtained for Wild-Type 
enzyme under the same conditions to allow easy comparison.  (e) The distance from Arg-105 to Glu-
174 throughout the MM trajectory for the Wild-type enzyme. 
 
Figure 4:  Molecular dynamics simulation of galactokinase R228K and R228M. (a) and (b) The 
secondary structured of residues 174-179 and 231-240 respectively. (c) RMSF by residue for R228K 
and R228M compared to WT galactokinase. 
 
Figure 5:  Molecular dynamics simulation of galactokinase E174D and E174Q. (a) and (b) The 
secondary structures for residues 174-179 and 231-240 respectively. (c) RMSF by residue for E174D 
and E174Q compared to WT galactokinase. 
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Table 1:  Steady-state kinetic parameters of human galactokinase and variants.  For experimental 
conditions, see Materials and Methods. 
Protein Km,ATP (µM) Km,Gal (µM) kcat (s
-1) kcat/Km,ATP (s
-1 mM-1) kcat/Km,Gal (s
-1 mM-1) 
Wild-type 4.0 ± 1.1 330 ± 70 1.7 ± 0.1 430 ± 110 10.1 ± 1.2 
E174D 3.9 ± 1.1 220 ± 70 1.6 ± 0.1 340± 74 7.6 ± 1.9 
R228M 9.4 ± 1.3 670 ± 130 2.3 ± 0.1 240 ± 30 3.3 ± 0.4 
R228K 14.9 ± 2.8 310 ± 100 3.7 ± 0.1 250 ± 40 19.6 ± 2.9 
R105M 8.3 ± 0.1 260 ± 130 0.7 ± 0.1 98 ± 9 2.7 ± 1.1 
 
Values are shown ± the standard error as determined by the fitting procedure.Table 2:  Thermal 
stability of human galactokinase and variants.  Tm values were determined using differential 
scanning fluorimetry.  Statistical significance was determined by ANOVA.
Protein Tm (°C) 
Wild-type 55.72 ± 0.34 
R105M 55.42 ± 0.15ns 
E174D 55.13 ± 0.35ns 
E174Q 52.50 ± 0.76*** 
R228K 51.30 ± 0.23*** 
R228M 51.68 ± 1.33*** 
 
Values are the mean of three determinations and are shown ± the standard errors of these means.  
One-way ANOVA was used to determine if Tm was significantly different from that determined for 
the wild-type enzyme.  ns, not significant (p>0.05); *** significant p<0.01. 
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Supplementary Figure S1:  Energy calculated per picosecond of simulation using the perl command in AmberTools. 
Supplementary Figure S1
Click here to download Supplementary Material (for online publication): Suppl Fig S1 energy.docx
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Supplementary Figure S2:  Root mean square deviation (rmsd) measured throughout the trajectory compared to the initial 
minimised structure. 
Supplementary Figure S2
Click here to download Supplementary Material (for online publication): Suppl Fig S2 rmsd.docx
E174D
0.0 0.1 0.2 0.3 0.4
0.00000
0.00005
0.00010
0.00015
0.00020
[ATP] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
E174D
0.0 0.5 1.0 1.5 2.0 2.5
0.00000
0.00005
0.00010
0.00015
[Gal] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R105M
0.0 0.2 0.4 0.6 0.8
0.00000
0.00005
0.00010
0.00015
0.00020
[ATP] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R228K
0.0 0.2 0.4 0.6 0.8
0.0000
0.0001
0.0002
0.0003
[ATP] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R228K
0.0 0.5 1.0 1.5 2.0 2.5
0.0000
0.0001
0.0002
0.0003
[Gal] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R105M
0.0 0.5 1.0 1.5 2.0 2.5
0.00000
0.00005
0.00010
0.00015
[Gal] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R228M
0.0 0.2 0.4 0.6 0.8
0.0000
0.0001
0.0002
0.0003
0.0004
[ATP] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
R228M
0.0 0.5 1.0 1.5 2.0 2.5
0.00000
0.00005
0.00010
0.00015
0.00020
0.00025
[Gal] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
WT
0.0 0.5 1.0 1.5 2.0 2.5
0.00000
0.00005
0.00010
0.00015
[Gal] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
WT
0.0 0.2 0.4 0.6 0.8
0.00000
0.00005
0.00010
0.00015
[ATP] (mM)
V
m
a
x
.a
p
p
(m
M
 N
A
D
H
/s
e
c
)
 
Supplementary Figure S3:  Steady state kinetics for wild-type human galactokinase and each of the variants studied here.  
Points are the mean of three determinations and error bars the standard errors of these means.  The lines were obtained 
by non-linear curve fitting as described in Materials and Methods. 
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Supplementary Figure S4: First derivative of differential scanning flourimetry data for human galactokinase and the 
variants studied here.  Values for Tm are reported in Table 2. 
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Supplementary Figure S4:  Native PAGE with increasing concentration of urea.  For details of conditions etc, please see Materials and 
Methods 
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